Amphastar Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.: A Detailed Gross Profit Analysis

Amphastar vs. BioCryst: A Decade of Profit Growth

__timestampAmphastar Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc.
Wednesday, January 1, 20145125600013486000
Thursday, January 1, 20157734700046361000
Friday, January 1, 201610418900023654000
Sunday, January 1, 20179079500023484000
Monday, January 1, 201810698500020182000
Tuesday, January 1, 201913192300044734000
Wednesday, January 1, 202014334000016136000
Friday, January 1, 2021199739000149906000
Saturday, January 1, 2022248860000264233000
Sunday, January 1, 2023351121000326751000
Loading chart...

Infusing magic into the data realm

A Tale of Two Biopharmaceutical Giants: Amphastar vs. BioCryst

In the dynamic world of biopharmaceuticals, Amphastar Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. have showcased remarkable growth trajectories over the past decade. From 2014 to 2023, Amphastar's gross profit surged by an impressive 585%, reflecting its robust market strategies and innovative product lines. Meanwhile, BioCryst demonstrated a staggering 2,320% increase in gross profit, underscoring its successful expansion and strategic investments in groundbreaking therapies.

Year-on-Year Growth

Amphastar's gross profit consistently climbed, with notable spikes in 2021 and 2023, where it reached 200% and 350% of its 2014 figures, respectively. BioCryst, on the other hand, experienced a dramatic leap in 2021, achieving a gross profit nearly 11 times that of 2014, and continued this upward trend into 2023.

Conclusion

These trends highlight the competitive landscape and the potential for innovation-driven growth in the biopharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025